Tagged Articles

Xarelto 217 articles

Second Xarelto side effects trial underway in PA

Johnson & Johnson’s Janssen Pharmaceuticals and Bayer failed to warn doctors about the significantly increased risk of internal bleeding their blood thinner Xarelto posed to patients who were also taking other antiplatelet medications, attorneys for a man suing the companies said during opening arguments in the second trial in a mass tort program in Philadelphia County. In 2013, Plaintiff Daniel Russell had a stent placed to treat a blocked coronary artery. He also had an irregular heartbeat. At that time, he was prescribed two anti-platelet medications, aspirin and Plavix, to prevent blood clots. Soon after, his heart was shocked back ... Read More

Second Xarelto trial underway in Philadelphia County

The second case among more than 1,700 in a mass tort program in Philadelphia County Court of Common Pleas over claims that the blood thinner Xarelto caused seious harm to patients, is scheduled to go to trial this week. The trial involves the case of Daniel Russell, who was prescribed Xarelto in May 2013 to prevent strokes after he was hospitalized with a heart condition. Seven days into his Xarelto treatment, Russell suffered a gastrointestinal bleed. He claims his major bleeding event was caused by Xarelto because at the time he was prescribed the drug he was already taking two ... Read More

Approval of Xarelto antidote still hangs in the air

A novel drug that reverses the blood thinning abilities of newer anticoagulants called Factor Xa inhibitors could control serious bleeding in patients. If approved by drug regulators, it would be the first antidote on the market that can reverse the effects of Factor Xa inhibition when potentially life-threatening major bleeding events occur. The drug’s effectiveness was suggested by clinical trial results presented at the American College of Cardiology’s 67th Annual Scientific Session. Factor Xa inhibitors work by inhibiting a protein involved in the formation of blood clots. Drugs in this class include Xarelto and Eliquis. They are used to prevent ... Read More

1,200 Xarelto cases to be prepped for trial

U.S. District Judge Eldon Fallon has ordered more than 1,200 cases alleging Johnson & Johnson’s Janssen Pharmaceuticals and Bayer’s blood thinner Xarelto caused severe injuries to be prepared for trials in courts across the country. Half of the cases were assigned for discovery by the end of April. The second wave will be selected by Aug. 30. Johnson & Johnson and its subsidiary Janssen face about 22,900 cases. Bayer faces about 22,000. All claim that the drug makers did not adequately warn doctors or patients about the risks associated with their blockbuster anticoagulant. Xarelto has been linked to bleeding events ... Read More

Xarelto makers don’t want patients to amend complaint

A month before a new round of bellwether trials is scheduled to begin in a mass tort program involving the blood thinner Xarelto, drug makers Johnson & Johnson’s Janssen Pharmaceuticals and Bayer have asked a Pennsylvania judge not to allow a substantially amended master complaint because they say it would significantly prejudice them in presenting a logical defense. There are 1,700 Xarelto-related cases in the mass tort program in the Philadelphia County Court of Common Pleas. The new master complaint lays out general allegations regarding bleeding risks on each case. Created in January 2015, the mass tort alleges that Janssen ... Read More

Woman fights to keep $28M Xarelto jury award

A woman’s near-$28 million jury verdict for injuries suffered while taking the blood thinner Xarelto was reversed last month, but she is fighting to get the compensation she believes she’s entitled to. Lynn Hartman has outlined issues she intends to raise with the Pennsylvania Superior Court in a brief challenging the Philadelphia Court of Common Pleas ruling to eliminate her $27.8 million award, the first win for plaintiffs in a multidistrict litigation accusing Xarelto makers Johnson & Johnson’s Janssen Pharmaceuticals and Bayer of not adequately warning about Xarelto side effects. Hartman’s appeal includes a challenge of Judge Michael Erdos’ statement ... Read More

Common aspirin as effective as Xarelto at preventing blood clots

The pricey blood thinner Xarelto is no better than common aspirin at preventing blood clots in patients who have recently undergone hip or knee replacement surgery, and bleeding risks between the two medications were similar, according to a study published in the New England Journal of Medicine. People who undergo hip or knee replacement surgeries are prone to developing blood clots, or venous thromboemboli (VTE), and are typically given blood thinners prophylactically. The study involved nearly 35,000 patients, all of whom were treated with Xarelto for five days after hip or knee replacement surgery. After five days, about half remained ... Read More

Woman fights to keep $28 million Xarelto jury award

A woman who was awarded $28 million in a bellwether case alleging the blood thinner Xarelto caused her life-threatening injuries argued that the Pennsylvania judge who axed her award ignored the fact that she would not have taken the drug if additional warnings had been added to its label. Instead, Judge Micahel Erdos threw out the first-of-its-kind verdict in January, siding with Xarelto makers Johnson & Johnson’s Janssen Pharmaceuticals and Bayer AG that the plaintiff’s doctor testified that additional warning on Xarelto would not have changed his decision to prescribe the drug. Lynn Hartman was awarded $28 million in December ... Read More

Xarelto possibly linked to cases of liver injury

Cases of liver injury in patients treated with the blood thinner Xarelto have been reported to the FDA’s Adverse Event Reporting System (FAERS) and flagged in the July to September 2017 quarterly review, but the agency has determined that no action is necessary at this time based on the available information. The appearance of a drug on the FAERS list does not mean that the FDA has concluded that the drug has the listed risk. It means that the agency has identified a potential safety issue. If after further review the FDA determines the drug is associated with the risk, ... Read More

Xarelto mass tort program in PA continues to grow

The Xarelto mass tort program in Philadelphia experienced the second-highest level of growth during 2017, jumping from 1,214 cases at the start of the year to 1,619 by year’s end, representing a 33 percent growth, according to court statistics. The only other mass tort program that grew more was that involving the antipsychotic Risperdal. Three Xarelto bellwether trials have already occurred in the federal multidistrict litigation (MDL) where another 20,000 lawsuits are currently pending. One case tried in Philadelphia resulted in a $27.8 million verdict for the plaintiff. The award was overturned and is currently on appeal to the Supreme ... Read More